Fluconazole 50mg/5mL Suspension

**Part A**

**Prescriber Criteria:** Consultant Hospital Doctor

**Inpatient use only:**
No authorization is needed for inpatient use.

**Part B**

**Prescriber Criteria:** Consultant

**Outpatient and Inpatient use:**
1. Chronic Kidney Disease – Renal Transplants Only
2. HIV/AIDS and HIV Related Diseases
3. Malignant Diseases
4. Primary Immunodeficiency Disorder
5. Secondary Immunodeficiency Disorder

Reserved for patient unable to swallow as:
- First-line treatment of candidiasis in non-neutropenic patients
- First-line empirical therapy for presumed invasive fungal infections in hospitalised patients.
- First-line treatment of mucosal (oropharyngeal, oesophageal, vulvovaginal) candidiasis.
- First-line treatment of mucosal candidiasis in immunocompromised patients.
- First-line prophylactic treatment in HIV patients to prevent relapse of underlying fungal infections
- Alternative induction treatment of cryptococcal disease in HIV patients where first and second line therapy (amphotericin/liposomal amphotericin + flucytosine) is inappropriate.
- Consolidation and maintenance treatment of cryptococcal disease.
- Alternative treatment of candidiasis in neutropenic patients where primary (caspofungin) and secondary (liposomal amphotericin) therapy is inappropriate
- Alternative prophylactic treatment of fungal infections during prolonged periods of neutropenia where standard therapy (itraconazole) is inappropriate.
- Alternative treatment of neonatal candidiasis where primary treatment (amphotericin or liposomal amphotericin) is inappropriate.

Other indications are to be considered on a case-by-case basis by members of the antibiotic team.

**Duration of Approval:**
1 year